Patents by Inventor Lilian A. Radesca

Lilian A. Radesca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline Efavirenz
    Patent number: 6673372
    Abstract: The potent reverse transcriptase inhibitor Efavirenz is produced in crystalline form. Crystalline Efavirenz exists in several physical forms which are-designated Forms 1, 2, 3 and 4, and are characterized by x-ray powder diffraction and differential scanning calorimetry. Pharmaceutical compositions and methods are useful for the treatment of the human immunodeficiency virus (HIV).
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: January 6, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Lilian A. Radesca, Michael B. Maurin, Shelley R. Rabel, James R. Moore
  • Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
    Patent number: 6555686
    Abstract: This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: April 29, 2003
    Assignee: Bristol-Myers Squibb Pharma
    Inventors: Rodney L. Parsons, Roberta L. Dorow, Akin H. Davulcu, Joseph M. Fortunak, Gregory D. Harris, Goss S. Kauffman, William A. Nugent, Lilian A. Radesca
  • Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
    Publication number: 20020035253
    Abstract: This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.
    Type: Application
    Filed: July 20, 2001
    Publication date: March 21, 2002
    Inventors: Rodney L. Parsons, Roberta L. Dorow, Akin H. Davulcu, Joseph M. Fortunak, Gregory D. Harris, Goss S. Kauffman, William A. Nugent, Lilian A. Radesca
  • Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
    Publication number: 20010044540
    Abstract: This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.
    Type: Application
    Filed: March 22, 2001
    Publication date: November 22, 2001
    Inventors: Rodney L. Parsons, Roberta L. Dorow, Akin H. Davulcu, Joseph M. Fortunak, Gregory D. Harris, Goss S. Kauffman, William A. Nugent, Lilian A. Radesca
  • Asymmetric synthesis of benzoxazinones
    Patent number: 6040480
    Abstract: The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1- benzoxazin-2-one of formula (VI-i) ##STR1## which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: March 21, 2000
    Assignee: Du Pont Pharmaceuticals Company
    Inventors: Michael E. Pierce, Cheng Y. Chen, Anusuya Choudhury, Lilian A. Radesca, Lushi Tan, Dalian Zhao
  • Asymmetric synthesis of benzoxazinones
    Patent number: 5925789
    Abstract: The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1- benzoxazin-2-one of formula (VI-i) ##STR1## which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.
    Type: Grant
    Filed: April 6, 1998
    Date of Patent: July 20, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Michael E. Pierce, Cheng Y. Chen, Anusuya Choudhury, Lilian A. Radesca, Lushi Tan, Dalian Zhao
  • Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS disorders
    Patent number: 5739158
    Abstract: Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders, convulsions and parkinsonism. Compounds of particular interest are of the formula ##STR1## wherein R.sup.1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms and loweralkenylloweralkyl; wherein each of R.sup.2 and R.sup.3 is independently selected from hydrido and loweralkyl; wherein each of R.sup.4 through R.sup.7, R.sup.10 and R.sup.
    Type: Grant
    Filed: July 1, 1992
    Date of Patent: April 14, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Brian R. de Costa, Kenner C. Rice, Nancy M. Gray, Patricia C. Contreras, Arthur E. Jacobson, Andrew Thurkauf, Lilian A. Radesca, Wayne D. Bowen, J. Michael Walker
  • Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders
    Patent number: 5571832
    Abstract: Compounds comprising a pyrrolidinyl ring are disclosed for use in the treatment of cerebral ischemia.
    Type: Grant
    Filed: June 20, 1994
    Date of Patent: November 5, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Brian R. de Costa, Wayne D. Bowen, Xiao-Shu He, Lilian Radesca, Kenner C. Rice
  • Method for preparing cyclic ureas and their use for the synthesis of HIV protease inhibitors
    Patent number: 5530124
    Abstract: This invention provides improved synthetic processes for the preparation of hydroxy-protected cyclic urea compounds of Formula (IX), ##STR1## which are useful as intermediates for the preparation of cyclic urea human immunodeficiency virus (HIV) protease inhibitors, from N-protected aminoaldehydes. The processes of the present invention provide high yields, can be conducted on multikilogram scale, and eliminate the need for chromatographic purification of intermediates or final product.
    Type: Grant
    Filed: June 30, 1994
    Date of Patent: June 25, 1996
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Lilian A. Radesca, Gregory D. Harris, Edward K. W. Wat, Robert E. Waltermire
  • Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS disorders
    Patent number: 5130330
    Abstract: Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders and convulsions. Compounds of particular interest are of the formula ##STR1## wherein R.sup.1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms, and loweralkenylloweralkyl; wherein each of R.sup.2 and R.sup.3 is independently selected from hydrido and loweralkyl; wherein each of R.sup.4 through R.sup.7, R.sup.10 and R.sup.
    Type: Grant
    Filed: January 31, 1990
    Date of Patent: July 14, 1992
    Assignee: G. D. Searle & Co.
    Inventors: Brian R. de Costa, Kenner C. Rice, Nancy M. Gray, Patricia C. Contreras, Arthur E. Jacobson, Andrew Thurkauf, Lilian A. Radesca, Wayne D. Bowen